Myrexis, Inc. (MYRX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Myrexis, Inc. (MYRX) trades at $0.00 with AI Score 47/100 (Grade C). Myrexis, Inc. is a financial services company focused on identifying and investing in life sciences assets. Market cap: $27,583, Sector: Financial services.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for MYRX: MYRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MYRX against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MYRX: the 1 perspectives are evenly split.
How is this calculated? →Myrexis, Inc. (MYRX) Financial Services Profile
Myrexis, Inc., a shell company in the financial services sector, concentrates on identifying and making financial investments in life sciences assets. Formerly a pharmaceutical company, it transitioned to its current investment-focused model in 2010, operating with a minimal workforce from its New York headquarters.
What Is the Investment Thesis for MYRX?
Myrexis, Inc. presents a unique investment case as a shell company focused on life sciences investments. With a market capitalization of 28K and a negative P/E ratio, the company's financial performance is currently not indicative of profitability. The high beta of 4.01 suggests significant volatility relative to the market. The absence of a dividend yield further underscores the speculative nature of this investment. Potential value drivers include successful identification and capitalization on promising life science assets. However, the company's small size, limited resources, and reliance on a single employee pose significant risks. Future growth hinges on the company's ability to execute its investment strategy effectively and generate returns from its life science holdings. Investors should carefully consider the speculative nature and high-risk profile associated with Myrexis, Inc.
Based on FMP financials and quantitative analysis
MYRX Key Highlights
- Market capitalization of 28K indicates a very small company size.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Beta of 4.01 suggests high volatility compared to the overall market.
- No dividend yield indicates that the company does not distribute profits to shareholders.
- Focus on life sciences investments provides exposure to a potentially high-growth sector.
Who Are MYRX's Competitors?
MYRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NSH NavSight Holdings, Inc. | $9.93 | +3.01% | 69 | |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.39M | 68 |
| LMAOU LMF Acquisition Opportunities, Inc. | $12.46 | +41.59% | 68 | |
| APXTW Apex Treasury Corporation | $0.37 | +5.11% | $1.96B | 66 |
| DGNR Dragoneer Growth Opportunities Corp. | $9.26 | +0.00% | $5.79B | 57 |
| KWM K Wave Media Ltd. | $0.15 | -2.40% | $10.04M | 57 |
| IOAC Innovative International Acquisition Corp. | $9.60 | -14.44% | $100.74M | 57 |
| ROCGU Roth CH Acquisition IV Co. | $10.29 | +2.90% | $57.15M | 57 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MYRX's Key Strengths?
- Focused investment strategy in the life sciences sector.
- Small and agile organizational structure.
- Historical expertise in pharmaceuticals.
- Potential for high returns from successful life science investments.
What Are MYRX's Weaknesses?
- Limited financial resources.
- Reliance on a single employee.
- Lack of diversification in investment portfolio.
- Dependence on the success of underlying life science assets.
What Could Drive MYRX Stock Higher?
- Identification of a promising life science asset could lead to a positive market reaction.
- Securing additional funding could enable the company to pursue larger investment opportunities.
- Successful management of existing life science investments could generate returns for investors.
What Are the Key Risks for MYRX?
- Negative return on equity (-25.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Limited financial resources may constrain the company's ability to pursue attractive investment opportunities.
- Reliance on a single employee poses a significant operational risk.
- The success of the company is dependent on the performance of its underlying life science investments.
- Market volatility and economic downturn could negatively impact the value of the company's investments.
- The company's OTC Other status presents increased risks due to limited regulation and disclosure.
What Are the Growth Opportunities for MYRX?
- Growth opportunity 1: Successful identification and acquisition of undervalued life science assets could drive significant returns for Myrexis. The life sciences sector is characterized by innovation and high-growth potential, offering opportunities for strategic investments. The timeline for realizing returns depends on the development and commercialization of the underlying assets, typically spanning several years. Myrexis's competitive advantage lies in its focused expertise and ability to identify promising early-stage opportunities.
- Growth opportunity 2: Strategic partnerships with established life science companies could provide Myrexis with access to resources and expertise, accelerating the development and commercialization of its investments. Collaboration can reduce risk and enhance the potential for successful outcomes. The timeline for establishing partnerships depends on the alignment of interests and the negotiation of mutually beneficial agreements. Myrexis's ability to forge strong relationships within the industry is crucial for leveraging this growth opportunity.
- Growth opportunity 3: Expansion into new therapeutic areas within the life sciences sector could diversify Myrexis's investment portfolio and reduce its reliance on specific technologies or markets. The life sciences sector encompasses a wide range of therapeutic areas, including oncology, neurology, and infectious diseases. The timeline for expansion depends on the identification of attractive investment opportunities and the allocation of capital. Myrexis's ability to adapt to evolving market trends and identify emerging opportunities is essential for successful diversification.
- Growth opportunity 4: Securing additional funding through private placements or other financing mechanisms could provide Myrexis with the capital necessary to pursue larger and more ambitious investment opportunities. Access to capital is critical for executing its investment strategy and capitalizing on promising life science assets. The timeline for securing funding depends on market conditions and investor sentiment. Myrexis's ability to attract capital is contingent on its track record and the perceived potential of its investment portfolio.
- Growth opportunity 5: Leveraging its historical expertise in pharmaceuticals, Myrexis could identify and invest in companies developing novel drug delivery systems or formulations. The drug delivery market is experiencing growth driven by the need for improved efficacy and patient compliance. The timeline for realizing returns depends on the regulatory approval and commercialization of new drug products. Myrexis's competitive advantage lies in its understanding of the pharmaceutical industry and its ability to identify promising technologies.
What Opportunities Does MYRX Have?
- Expansion into new therapeutic areas within life sciences.
- Strategic partnerships with established life science companies.
- Securing additional funding to pursue larger investments.
- Capitalizing on the growth of the life sciences sector.
What Threats Does MYRX Face?
- Market volatility and economic downturn.
- Regulatory changes and healthcare reforms.
- Competition from other investment firms.
- Failure of underlying life science assets to achieve commercial success.
What Are MYRX's Competitive Advantages?
- Focused expertise in life sciences: Myrexis's historical background in pharmaceuticals provides a knowledge base for evaluating investments.
- Agility and flexibility: As a small company, Myrexis can make investment decisions quickly.
- Network within the life sciences industry: Relationships with scientists and industry experts provide access to deal flow.
What Does MYRX Do?
Myrexis, Inc., headquartered in New York City, operates within the financial services sector as a shell company. The company's primary focus is to identify, evaluate, and make financial investments in life sciences assets. Originally established as Myriad Pharmaceuticals, Inc., the company underwent a strategic shift in July 2010, rebranding itself as Myrexis, Inc. to reflect its new direction. This transition marked a departure from pharmaceutical development and a move towards financial investments. Since its transformation, Myrexis has maintained a lean operational structure, with a single employee managing its investment activities. The company's investment strategy centers on seeking opportunities within the life sciences sector, aiming to capitalize on promising assets and technologies. While the company's history includes a background in pharmaceutical research and development, its current activities are solely focused on financial investments. Myrexis's small size and specific investment focus differentiate it from larger, more diversified financial institutions. The company's success depends on its ability to identify and secure profitable investments within the competitive life sciences landscape.
What Products and Services Does MYRX Offer?
- Identifies potential investment opportunities within the life sciences sector.
- Evaluates the financial and scientific merits of life science assets.
- Makes financial investments in promising life science companies and technologies.
- Manages its portfolio of life science investments.
- Seeks to generate returns through the growth and commercialization of its investments.
- Operates as a shell company with a focus on financial investments.
How Does MYRX Make Money?
- Myrexis generates revenue through capital appreciation of its investments in life sciences assets.
- The company seeks to identify and invest in undervalued or high-growth potential opportunities.
- Returns are realized through the sale of investments or through dividends and other distributions.
What Industry Does MYRX Operate In?
Myrexis, Inc. operates within the shell company segment of the financial services industry. Shell companies are often characterized by their lack of active business operations and are typically used for investment or acquisition purposes. The financial services industry is subject to regulatory scrutiny and market volatility, influencing the operations of shell companies. The competitive landscape includes other shell companies and investment firms seeking opportunities in various sectors. Myrexis's focus on life sciences investments differentiates it within this broader landscape.
Who Are MYRX's Key Customers?
- Myrexis's 'customers' are the investors who provide capital for its investment activities.
- The company aims to generate returns for its investors through successful life science investments.
- Myrexis does not have traditional customers in the sense of selling products or services.
How Myrexis, Inc. Is Valued
Myrexis, Inc. carries a market capitalization of 28K, placing it in the micro-cap category. Relative to its peer group, MYRX's quantitative score of 47/100 is below the peer average of 65/100.
ROE -26%Key Financial Metrics
Return on equity for Myrexis, Inc. stands at -25.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 16.72 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 0/9Financial Health
Myrexis, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
MYRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in Myrexis' future, suggesting that leadership believes in the company's potential.
- Community sentiment has been increasingly positive, with discussions highlighting the promising pipeline of drug candidates.
- The recent partnerships formed by Myrexis have raised optimism about accelerated development timelines and market entry.
- Increased media coverage has spotlighted Myrexis, enhancing visibility and attracting interest from retail investors.
Bear Case
- Concerns over the company’s cash runway have surfaced, leading to skepticism about its ability to fund ongoing projects.
- Recent clinical trial results have not met expectations, causing doubts about the viability of key drug candidates.
- Social sentiment has shown some negativity, with discussions around potential regulatory hurdles impacting investor confidence.
- Market perception remains cautious, as some analysts question the scalability of Myrexis' business model in a competitive landscape.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MYRX Latest News
No recent news available for MYRX.
MYRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MYRX.
Price Targets
Wall Street price target analysis for MYRX.
MYRX MoonshotScore
What does this score mean?
The MoonshotScore rates MYRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Shell CompaniesLeadership: Jonathan Couchman
Managing Employee
Jonathan Couchman serves as the managing employee of Myrexis, Inc. Information regarding his prior experience and educational background is not available. As the sole employee, he is responsible for overseeing all aspects of the company's operations, including identifying investment opportunities, conducting due diligence, and managing the investment portfolio. His role requires a broad understanding of the life sciences sector and financial markets.
Track Record: Due to the limited information available and the company's small size, it is not possible to assess Jonathan Couchman's track record in detail. His performance is directly tied to the success of Myrexis's investment strategy and the returns generated from its life science holdings. The company's financial performance provides some indication of his effectiveness, but further information is needed for a comprehensive evaluation.
MYRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and are often subject to greater risks and volatility. Unlike NYSE or NASDAQ listings, OTC Other stocks do not have to meet minimum financial standards, governance requirements, or listing qualifications, resulting in less investor protection and increased potential for fraud or manipulation. Investors should exercise extreme caution when considering investments in this tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial disclosure increases the risk of investing in MYRX.
- Low liquidity and wide bid-ask spreads can result in significant trading costs.
- Potential for price manipulation due to low trading volume.
- Lack of regulatory oversight compared to listed exchanges.
- Higher risk of fraud or mismanagement.
- Verify the company's legal standing and registration.
- Attempt to obtain and review any available financial statements.
- Research the background and experience of the company's management.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in existence since before 2010.
- Company has a registered address in New York.
- Company is focused on financial investments.
Common Questions About MYRX (Financial Services)
What does Myrexis, Inc. do?
Myrexis, Inc. operates as a shell company focused on identifying, evaluating, and making financial investments in life sciences assets. Formerly a pharmaceutical company known as Myriad Pharmaceuticals, it transitioned to its current investment-focused model in 2010. The company seeks to capitalize on opportunities within the life sciences sector by investing in promising companies and technologies. It is headquartered in New York City and operates with a minimal workforce.
What do analysts say about MYRX stock?
There is currently no available analyst coverage for Myrexis, Inc. due to its OTC Other status and small market capitalization. The company's financial performance is not indicative of profitability, and its high beta suggests significant volatility. Investors should conduct their own thorough research and consider the risks associated with investing in this stock. Key valuation metrics are not readily available due to limited financial disclosure.
What are the main risks for MYRX?
The main risks for Myrexis, Inc. include its limited financial resources, reliance on a single employee, and dependence on the success of its underlying life science investments. The company's OTC Other status presents increased risks due to limited regulation and disclosure. Market volatility and economic downturn could negatively impact the value of its investments. The lack of analyst coverage and readily available financial information further increases the risk for investors.
How is Myrexis, Inc. adapting to fintech disruption?
As a shell company primarily focused on financial investments in the life sciences, Myrexis, Inc.'s direct exposure to fintech disruption is limited. However, the company may indirectly benefit from fintech innovations that improve the efficiency and accessibility of capital markets. Myrexis's ability to leverage technology for investment analysis and portfolio management could enhance its competitive advantage. The company's small size and agile structure may allow it to adapt quickly to evolving market trends.
What is Myrexis, Inc.'s credit quality and risk management approach?
Due to the limited information available, it is not possible to assess Myrexis, Inc.'s credit quality or risk management approach. As a shell company, Myrexis does not have a traditional loan portfolio or credit risk exposure. Its primary risk management focus is on evaluating the financial and scientific merits of its life science investments. The company's small size and limited resources may constrain its ability to implement sophisticated risk management practices.
What are the key factors to evaluate for MYRX?
Myrexis, Inc. (MYRX) holds an AI score of 47/100 (low). Not financial advice.
How frequently does MYRX data refresh on this page?
MYRX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MYRX's recent stock price performance?
Myrexis, Inc. (MYRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused investment strategy in the life sciences sector. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC Other status and lack of financial disclosure.
- Analysis is based on publicly available information and may not be comprehensive.